IP Library Granted Patent US 7,888,066
Granted Patent B2
US 7,888,066 · App. 12/353,196 · Granted Feb 15, 2011

Methods for identifying substances for the treatment of Alzheimer's disease

Assignee: Mount Sinai School of Medicine
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,888,066
App. No.
12/353,196
Granted
Feb 15, 2011
Kind
B2
Abstract

The present invention relates to a method for diagnosing Alzheimer's disease and Parkinson's disease in a subject by analyzing the expression of Semaphorin 3 and downstream effectors. It also provides a method for identifying a substance useful in the prevention or treatment of Alzheimer's disease and Parkinson's disease, and a method of using such substance in the treatment of Alzheimer's disease and Parkinson's disease.

Claims (7)

1. A method for identifying a test substance useful in the treatment of Alzheimer's disease, which method comprises the following steps:

(a) contacting a test neuronal cell with the test substance and Semaphorin 3A protein under conditions wherein the addition of the Semaphorin 3A protein alone induces withdrawal, retraction or collapse of the nerve growth cone;

(b) contacting a control neuronal cell with the Semaphorin 3A protein alone under the same conditions;

(c) comparing withdrawal, retraction or collapse of the nerve growth cone in the test neuronal cell of step (a) and the control neuronal cell of step (b);

(d) identifying as a substance useful for the treatment of Alzheimer's disease the test substance which inhibits withdrawal, retraction or collapse of the nerve growth cone in the test neuronal cell of step (a) as compared to the control neuronal cell of step (b); and

(e) administering the test compound identified as useful for the treatment of Alzheimer's disease in step (d) to an animal model of Alzheimer's disease.

2. The method according to claim 1 , wherein the Semaphorin 3A is human Semaphorin 3A.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 7, 2016
From: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039276/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2010
From: GOOD, PAUL F.; KOHTZ, D. STAVE
To: MOUNT SINAI SCHOOL OF MEDICINE
Reel/Frame 025471/0146 →
Continuity (4)
Continuation 11147022 · Jun 6, 2005
Division 10200001 · Jul 19, 2002
Provisional Application 60306827 · Jul 20, 2001
Related Publication 20090136990A1 · May 28, 2009